DIRC3 and near NABP1 genetic polymorphisms are associated laryngeal squamous cell carcinoma patient survival
Metrics: PDF 707 views | HTML 1151 views | ?
Zhen Shen1,*, Wanli Ren1,*, Yanxia Bai1, Zhengshuai Chen3,4, Jingjie Li3,4, Bin Li3,4, Tianbo Jin3,4, Peilong Cao2, Yuan Shao1
1Department of Otolaryngology & head neck, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China
2Department of Pathology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China
3School of Life Sciences, Northwest University, Xi’an, Shaanxi 710069, China
4National Engineering Research Center for Miniaturized Detection Systems, Xi’an 710069, China
*These authors have contributed equally to this work
Peilong Cao, email: email@example.com
Yuan Shao, email: firstname.lastname@example.org
Keywords: laryngeal squamous cell carcinoma, NABP1, DIRC3, biomarker, polymorphism
Received: August 11, 2016 Accepted: October 14, 2016 Published: October 25, 2016
Laryngeal squamous cell carcinoma (LSCC) is one of the most common and aggressive malignancies of the upper digestive tract. The present study is a retrospective analysis of data from a prospective longitudinal study. A total of 170 male LSCC patients (average age, 60.75±10.082) at the First Affiliated Hospital of Xi’an Jiaotong University School of Medicine were recruited between January 2002 and April 2013 for this study. We assessed correlations between patient characteristics and survival, and sequenced genomic DNA from patient peripheral blood samples. We found that the single nucleotide polymorphisms (SNPs), rs11903757, with closest proximity to NABP1 and SDPR, and rs966423 in DIRC3, were associated with survival in LSCC patients. Median follow-up was 38 months (range 3–122) and median survival time was 48 months. LSCC patients with total laryngectomy, poor differentiation, T3-T4 stage, N1-N2 stage or III-IV TNM stage had reduced survival. This is the first study to demonstrate that the rs11903757 GT (HR=2.036; 95% CI, 1.071–3.872; p=0.030) and rs966423 TT (HR=11.677; 95% CI, 3.901–34.950; p=0.000) genotypes predict poor patient outcome. These polymorphisms may serve as useful clinical markers to predict patient survival, and to guide individual patient therapeutic decisions.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.